Report Sections

See All Reports

Coronavirus Infections (819) Severe Acute Respiratory Syndrome (567) Infection (472) Pneumonia (366) Communicable Diseases (199) Respiratory Distress Syndrome, Adult (179) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) Respiratory Insufficiency (132) Syndrome (105) Virus Diseases (90) Pneumonia, Viral (82) Depression (67) Critical Illness (62) Anxiety Disorders (41) Cardiovascular Diseases (36) Emergencies (36) Respiratory Tract Infections (36) Stress, Psychological (31) Hypoxia (30) Inflammation (30) Lung Injury (30) Neoplasms (30) Wounds and Injuries (30) Stress Disorders, Post-Traumatic (29) Thrombosis (28) Diabetes Mellitus (26) Disease (26) Respiratory Tract Diseases (26) Depressive Disorder (25) Stress Disorders, Traumatic (25) Lung Diseases (23) Acute Kidney Injury (22) Disease Progression (22) Mental Disorders (21) Olfaction Disorders (20) Respiration Disorders (20) Burnout, Psychological (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Dyspnea (12) Fibrosis (12) Influenza, Human (12) Arthritis, Rheumatoid (11) Rheumatic Diseases (11) Venous Thrombosis (11) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Heart Failure (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Infarction (8) Liver Diseases (8) Lung Diseases, Obstructive (8) Multiple Sclerosis (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Autoimmune Diseases (7) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lymphopenia (7) Pulmonary Disease, Chronic Obstructive (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Adenoviridae Infections (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Nervous System Diseases (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Colorectal Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Fibromyalgia (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Sleep Initiation and Maintenance Disorders (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Ageusia (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bipolar Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypersensitivity (3) Hypertension, Pulmonary (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) Muscle Weakness (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Myofascial Pain Syndromes (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Atrophy (2) Bacteremia (2) Behcet Syndrome (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Cerebral Palsy (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Common Cold (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) Constriction, Pathologic (2) Coronavi (2) Dementia (2) Depressive Disorder, Major (2) Developmental Disabilities (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Esophageal Neoplasms (2) Eye Diseases (2) Fever (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Ischemia (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Muscular Atrophy (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) Osteoporosis (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) Scleroderma, Diffuse (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Skin Diseases (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Agoraphobia (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) Com (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Conversion Disorder (1) Coron (1) Coronavirus Infect (1) Cr (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) DiGeorge Syndrome (1) Diabetes Complications (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Emergen (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gastrointestinal Neoplasms (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyp (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) Inf (1) Infant, Newborn, Diseases (1) Infe (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intestinal Neoplasms (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Dystrophies (1) Musculoskeletal Diseases (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neurodegenerative Diseases (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pn (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Renal Insufficie (1) Reperfusion Injury (1) Resp (1) Respi (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) Se (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Tracheal Stenosis (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D060825: Cognitive Dysfunction

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (31)


Name (Synonyms) Correlation
drug3339 Telehealth phone calls Wiki 0.33
drug2170 Neurocognitive assessment Wiki 0.33
drug373 BGB-DXP593 Wiki 0.33
Name (Synonyms) Correlation
drug835 Community popular opinion leader (POL) based intervention Wiki 0.33
drug1668 Instrumental Activities of Daily Living Shaping Wiki 0.33
drug833 Communication type Wiki 0.33
drug3644 Volunteer of TIP-OA Program Wiki 0.33
drug842 Comparator Wiki 0.33
drug828 Combination Wiki 0.33
drug1006 Deep Breathing training Wiki 0.33
drug1451 High Intensity Interval Training group Wiki 0.33
drug3466 Transfer Package from CI Therapy Wiki 0.33
drug823 Collection of odour samples Wiki 0.33
drug847 Completion of post telemedicine encounter survey Wiki 0.33
drug849 Completion of survey after peak of pandemic Wiki 0.33
drug3385 The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19 Wiki 0.33
drug856 Conjunctival swab and nasopharyngeal swab Wiki 0.33
drug2683 Psycho-education Wiki 0.33
drug639 COVID-19 swap test PCR Wiki 0.33
drug2227 No research related technology based social interactions Wiki 0.33
drug848 Completion of pre-pandemic survey Wiki 0.33
drug3328 Technology based social interactions Wiki 0.33
drug3151 Speed of Processing Training Wiki 0.33
drug3689 Yoga group Wiki 0.33
drug3086 Sham Wiki 0.33
drug3344 Telephone interview Wiki 0.33
drug843 Compassion focused intervention Wiki 0.33
drug3161 Stakeholder of TIP-OA Program Wiki 0.33
drug1564 Hyperbaric oxygen Wiki 0.24
drug3557 Usual Care Wiki 0.11
drug2490 Placebo Wiki 0.02

Correlated MeSH Terms (8)


Name (Synonyms) Correlation
D000544 Alzheimer Disease NIH 0.33
D008569 Memory Disorders NIH 0.33
D003072 Cognition Disorders NIH 0.33
Name (Synonyms) Correlation
D004827 Epilepsy NIH 0.33
D012640 Seizures NIH 0.24
D003704 Dementia NIH 0.24
D009422 Nervous System Diseases NIH 0.15
D020521 Stroke NIH 0.09

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0001268 Mental deterioration HPO 1.00
HP:0002354 Memory impairment HPO 0.33
HP:0002511 Alzheimer disease HPO 0.33
Name (Synonyms) Correlation
HP:0000726 Dementia HPO 0.24
HP:0001250 Seizure HPO 0.19
HP:0001297 Stroke HPO 0.09

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials


1 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

NCT04377425
Conditions
  1. Neurological Diseases or Conditions
  2. Stroke, Acute
  3. Seizure Disorder
Interventions
  1. Diagnostic Test: COVID-19 swap test PCR
MeSH:Stroke Seizures Nervous System Diseases Epilepsy Cognition Disorders Cognitive Dysfunction
HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

Primary Outcomes

Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

Time: 6 months

Secondary Outcomes

Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

Measure: Three months cognitive function of COVID-19 positive patients

Time: 3 months

Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

Time: 6 months

Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

Time: 6 months

Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

Measure: Anosmia in COVID-19 positive patients

Time: 6 months

Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

Time: 24 months

Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

Time: 24 months
2 Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia

Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact. The Spanish government has enforced social distancing, quarantine and home confinement. This restriction of daily life activities and separation from loved ones may lead to social isolation and loneliness with health-related consequences in community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers. Additionally, an inadequate access to healthcare and social support services may aggravate chronic conditions. Technology home-based interventions emerge for combating social isolation and loneliness preventing the risk of viral exposure. The aim of this multicentre cohort study is to explore, analyze and determine the impact of social isolation on: 1) cognition, quality of life, mood, technophilia and perceived stress of community-dwelling older adults with mild cognitive impairment or mild dementia, and on caregiver burden; 2) health and social care services access and utilization, and 3) cognitive, social and entertainment use of ICTs. This study will be conducted in two Spanish regions Andalucía (Málaga) and Cataluña (Tarrasa). In total 200 dyads, consisting of a person with mild cognitive impairment or mild dementia (PMCI/MD) and their informal caregiver will be contacted by telephone. Potential respondents will be participants of the SMART 4 MD (N=100) and TV-AssistDem (N=100) clinical trials. The change in means in the variables will be analyzed comparing baseline results in the previous studies with those during and after confinement using the ANOVA test of repeated measures or the non-parametric Friedman test if appropriate. The performance of a multivariate analysis of variance (ANCOVA) to introduce possible covariates will also be contemplated. A 95% confidence level will be used.

NCT04385797
Conditions
  1. Mild Cognitive Impairment
  2. Dementia
Interventions
  1. Other: Telephone interview
MeSH:Dementia Cognitive Dysfunction
HPO:Cognitive impairment Dementia Mental deterioration

Primary Outcomes

Description: The Mini-Mental State Examination (MMSE) (23) will be used to assess the cognitive function of the PMCI/MD. The most common cutoff scores for cognitive impairment and dementia are ranging 23 to 27 over 30. As telephone call interviewing will be the safest means to communicate with the PMCI/MD during and after the COVID-19 pandemic the 22 items telephone version of the MMSE will be used (24). All points of the MMSE can be covered in the telephone version except the last section assessing language and motor skills. In the phone version, we will ask the subject to repeat a phrase and name one item (For example: "Tell me, what is the name of the object you are using to talk to me?"). However, a second item will be not be named, nor will be the person be asked to follow a three-stage command, read and obey a sentence, write a sentence, or copy an intersecting pentagon as in the original version.

Measure: Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Secondary Outcomes

Description: The Quality of Life-Alzheimer's Disease Scale (QoL-AD) (19-22) is an instrument specifically designed to measure QoL in PMCI/MD from the perspective of both the patient and the informal caregiver. It is a 13-item measure, which includes assessments of the person´s relationships with friends and family, financial situation, physical condition, mood, memory, and an overall assessment of life quality. Response are 4-point multiple choice options (1 = poor, 2= fair, 3= good, 4 = excellent). Scale scores range from 13 to 52, with higher scores indicating greater quality of life. When cognitive function may be compromised, informal caregivers will complete the QoL-AD, on behalf of the PMCI/MD.

Measure: Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The European Quality of Life 5 Dimensions 3 Levels (EuroQoL-5D-3L) is a standardized generic instrument consisting of a descriptive system and a visual analogue scale (VAS). The descriptive system comprises 5 dimensions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems. A 1-digit number expresses the level selected for that dimension. The digits can be combined into a 5-digit number that describes the patient's health state. The VAS records the patient's self-rated health on a vertical scale, where the endpoints are 100 = 'The best health you can imagine' and 0 = 'The worst health you can imagine'. EuroQoL-5D-3L has been shown to correlate well with QoL-AD, indicating that using both measures side-by-side is compatible.

Measure: Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Short Form of the Geriatric Depression Scale (GDS) (25) will be used to assess mood. Of the 15 items, 10 indicate depression when answered positively, while the rest (1, 5, 7, 11, 13) when answered negatively. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 moderate depression, and 12-15 severe depression.

Measure: Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Instrument for Measuring Older People's Attitudes Toward Technology (TechPH) measures older people's attitudes and enthusiasm for health technology (26). This instrument refers to technophilia as a person's enthusiasm for and positive feelings toward their technology use and absence of the fears and doubts some older people could have about their ability to manage using new technology. The six items of the instrument measure two factors of technophilia: 3 items concerning techEnthusiasm and 3 items techAnxiety. Response are constructed with a five-point Likert scale questionnaire, ranging from 1 (fully disagree) to 5 (fully agree).

Measure: Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The scale has 10 questions regarding feelings and thoughts during the last month and are rated according to frecuency 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items

Measure: Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Zarit Burden Interview (ZBI-12) is a 12-item scale with each answer chosen from a 5-point Likert scale (Nearly always=4, Quite frequently=3, Sometimes=2, Rarely=1, Never=0). It is a shortened version of the original scale, was developed specifically for informal caregivers of PMCI/MD and covers issues such as caregiver stress and the degree to which caring is affecting their health and social life. Total score range 0 to 48 (0-10= no to mild burden, 10-20= mild to moderate burden >20= high burden).

Measure: Change on caregiver burden prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Client Service Receipt Inventory (CSRI) (32,33) scale will be used to evaluate the service utilization. This scale is an internationally used method for gathering data on service utilization and other domains relevant for economic analysis of mental health care. It has five sections: background client information, accommodation and living situation, employment history, earnings and benefits, a record of services usually used and information about informal caregiver support. The sections assessed will be consultations, admissions and visits, grouped into subsections according to hospital, specialist, primary or home care. Treatment related to hospital admissions or illness exacerbation will also be assessed. It´s adaptability ensures it is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.

Measure: Change on healthcare and social support services access prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: Use of ICTs (SmartPhone, Tablet, Computer, Smart-TV, or other) to contact healthcare and social support services, to stimulate cognition, to facilitate social connectedness (telephone call, video call, texting...), to access COVID-19 information and to enable entertainment.

Measure: Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.

Time: Through study completion, an average of 6 months
3 Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment

The current study will examine the impact of frequent social interaction through communication technologies during COVID-19 pandemic in the cognitive status of socially-isolated older adults with and without cognitive impairment. Patients will take place in an experimental crossover study, participants will complete one month of an intervention and one month of as passive control. The goal of this study is to determine: A.) if frequent social interaction through ICT during COVID-19 pandemic will have a significant positive impact in cognitive performance on testing, and B.) how social isolation and cognitive status influence misconceptions around the current pandemic.

NCT04480112
Conditions
  1. Memory Disorders
  2. Alzheimer Disease
  3. Mild Cognitive Impairment
Interventions
  1. Behavioral: Technology based social interactions
  2. Other: No research related technology based social interactions
MeSH:Alzheimer Disease Memory Disorders Cognitive Dysfunction
HPO:Alzheimer disease Cognitive impairment Memory impairment Mental deterioration

Primary Outcomes

Description: The Oral Trail Making Test B (TMT-B) will be used to assess memory performance. It is a neuropsychological measure that provides an assessment of sequential set-shifting. Participants are asked to count from 1 to 25 switching between number and letter, eg 1-A-2-B-3-C, until stopped.

Measure: Change in memory performance

Time: Baseline,1 month

Description: Repeatable Battery for the Assessment of Neuropsychological Status (R-BANS) will be administered to assess cognitive decline or improvement. The 12 items on the RBANS assess five cognitive domains: immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory. Scores can range from 0-160 and are interpreted as: 130 and above- very superior; 120-129 - superior; 110-119- high average; 90-109- average; 80-89- low average; 70-79- borderline; 60 and below extremely low.

Measure: Change in cognition

Time: Baseline, 1 month

Description: Phonemic fluency will be assessed by asking participants to produce orally as many words as possible beginning with a specific letter or for a specific category (eg animals, fruits, etc). The test consists of three trials, of 1 min each. The higher the number of words provided, the greater the verbal fluency.

Measure: Change in phonemic fluency

Time: Baseline, 1 month

Secondary Outcomes

Description: The 6-item version of the Lubben Social Network scale (LSNS-6) will be used to assess social isolation. For each of the 6 questions the participant rates from 0 to 5 their perceived social engagement where 0=less social engagement and 5= more social engagement. The summed total score ranges between 0 and 30. Lower total scores indicate more social isolation.

Measure: Social isolation

Time: 1 month

Description: Loneliness will be assessed using the UCLA loneliness scale. Participants rate each item as either O ("I often feel this way"= 3),S ("I sometimes feel this way"=2), R ("I rarely feel this way"=1), N ("I never feel this way"=0). A total score is computed by adding up the response to each question and can range from 0 to 60. The average loneliness score on the measure is 20. A score of 25 or higher reflects a high level of loneliness. A score of 30 or higher reflects a very high level of loneliness.

Measure: Loneliness

Time: 1 month

Description: The Geriatric Depression Scale (GDS) will be used to assess depression. It consists of 15 questions- 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

Measure: Depressive symptoms

Time: 1 month

Description: An investigator developed questionnaire based on survey results published by Geldsetzer P in Annals of Internal Medicine, 3-2020 will be used to assess Covid-19 misinformation.

Measure: Misinformation about Covid-19

Time: 1 month
4 Telehealth Intervention Program for Older Adults (TIP-OA) Struggling With Mental Health/Cognitive Issues

COVID-19 is having profound effects on older adults' due to social isolation measures which may negatively impact individuals' mental and physical health. Recently, a telephone program, the Telehealth Intervention Program for Older Adults (TIP-OA), was created. In this program, a volunteer is calling older adults (age≥60) every week to have a friendly conversation. The objective of this study is to evaluate the effectiveness of this telephone program (TIP-OA) in reducing stress, improving the mental health of program users, and understand their experiences.

NCT04523610
Conditions
  1. Depression, Anxiety
  2. Cognitive Impairment
  3. Stress
Interventions
  1. Behavioral: Telehealth phone calls
  2. Other: Volunteer of TIP-OA Program
  3. Other: Stakeholder of TIP-OA Program
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Description: Perceived Stress Scale (PSS) is a 14-item scale used to measure the degree to which life events are experienced and appraised as stressful. It asks respondents about how often they have felt certain ways in the past month, with responses ranging from 0 (never) to 4 (very often).

Measure: Perceived Stress Scale (PSS)

Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

Description: Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report questionnaire used to diagnose depression and assess symptom severity. The questionnaire asks individuals how often in the last two weeks they have been bothered by problems like "feeling down, depressed, and hopeless" and "poor appetite or overeating." Scores for each question include 0 (not at all), 1 (several days), 2 (more than half of the days), and 3 (nearly every day).

Measure: Patient Health Questionnaire-9 (PHQ-9)

Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

Description: Generalized Anxiety Disorder-7 (GAD-7) is a 7-item scale that measures symptoms of anxiety present in the previous 2 weeks. Respondents can choose from a score of 0 (not at all sure), 1 (several days), 2 (over half the days), or 3 (nearly every day). Items include "Not being able to stop or control worrying" and "Being so restless that it's hard to sit still".

Measure: Generalized Anxiety Disorder-7 (GAD-7)

Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

Description: Fear of COVID-19 Scale is an 18-item scale measuring individuals' anxiety, fear and concern surrounding the COVID-19 pandemic. Items include: "Fear that I will be infected" and "Worry if I will be assigned to COVID wards if hospitalized" (34).

Measure: Fear of COVID-19 Scale

Time: Change from Baseline to 4- and 8-weeks (15 minute assessment)

Secondary Outcomes

Description: What are the roles, contributions, and challenges of volunteers in identifying the needs of program users and volunteers, providing access to services, and creating appropriate responses to identified needs for the success and efficacy of the program?

Measure: Interviews and Focus Groups with Volunteers

Time: 8-weeks (2 hours)

Description: What are the roles, contributions, and challenges of different stakeholders (e.g. community partners, program organizers, and clinicians) in identifying the needs of program users and volunteers, providing access to services, and creating appropriate responses to identified needs for the success and efficacy of the program?

Measure: Interviews and Focus Groups with Stakeholders

Time: 8-weeks (2 hours)

Description: What are the experiences and evaluation of the program users about their engagement with the TIP-OA? Has the program contributed in improving the health of the program users?

Measure: Interviews with Program Users

Time: 8-weeks (2 hours)
5 NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients

Critically ill patients requiring intensive care suffer to a large extent from cognitive deficits involving higher brain functions that primarily affect memory, learning and the ability to concentrate. While the background to this effect is not fully understood, there are growing evidence to support mechanisms related to neuro inflammation and changes in blood flow with concomitant ischemic brain damage. Patients with covid-19 often suffer from severe inflammatory activity with an increased risk of coagulation abnormalities and brain damage. Covid-19 patients requiring intensive care develope more severe impairment of neurological and cognitive function than critically ill intensive care patients who have not covid-19. This project therefore aims to map the link between inflammation, immunology and coagulation systems as well as biochemical and structural changes in the brain with cognitive effects in patients in intensive care for covid-19.

NCT04578197
Conditions
  1. Covid19
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Measure: The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder

Time: Up to 12 months

Measure: The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder

Time: Up to 12 months

Measure: The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder

Time: Up to 12 months

Secondary Outcomes

Measure: The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

Time: Up to 12 months

Measure: The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

Time: Up to 12 months

Measure: The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder

Time: Up to 12 month

Description: Markers of inflammation impact - in relation to cerebrospinal fluid changes .

Measure: Blood biomarker changes of inflammation impact

Time: Up to 3 months

Description: Markers of neurological impact - in relation to cerebrospinal fluid changes .

Measure: Blood biomarker changes of neurological impact

Time: Up to 3 months

Description: Neurological impact in relation to cerebrospinal fluid changes

Measure: Neuroradiological changes

Time: Up to 3 months

Description: in relation to cerebrospinal fluid changes/blood

Measure: Clinical course - Pulmonary gas exchange

Time: Up to 3 months

Description: in relation to cerebrospinal fluid changes/blood

Measure: Clinical course - Lung function recording

Time: Up to 3 months

Description: Patient ICU care data - in relation to cerebrospinal fluid changes

Measure: Patient characteristics

Time: Up to 3 months
6 Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study

Acute Respiratory Distress syndrome (ARDS) is a pulmonary systematic inflammatory response, leading to acute respiratory failure with hypoxia and/or hypercarbia. COVID-19 evokes a viral pneumonia, which may result in ARDS as well. It is not yet clear if COVID-19 disease behaves like the typical ARDS. Corona virus causes primarily deep hypoxia. Hypoxia, on its own, can lead to long term cognitive impairment. However, critical illness also affects long-term neurocognitive functioning. The investigators will be researching the possibility of long-term cognitive impairment in COVID-19 ICU patients, in comparison with reference values of a healthy population as well as the values measured in critically ill patients, admitted not only for respiratory reasons.

NCT04593069
Conditions
  1. Covid19
  2. Cognitive Impairment
Interventions
  1. Behavioral: Neurocognitive assessment
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Description: the Repeatable Battery for the Assessment of Neuropsychological Statusis (RBANS) is a neuropsychological test that provides information about 5 domains of cognition (1) immediate and (2) delayed memory, (3) attention, (4) visuospatial construction and (5) language) and provides a total score. It is a test that takes about 30 minutes and consists of twelve tests. These are: (1) List Learning, (2) Story Memory, (3) Figure Copy, (4) Line Orientation, (5) Picture Naming, (6) Semantic Fluency, (7) Digit Span, (8) Coding, (9) List Recall, (10) List Recognition, (11) Story Recall and (12) Figure Recall. According to the RBANS manual, the possible values for the RBANS scores at the item, domain, and scale level are 0 to 89, 40 to 154, and 40 to 160

Measure: Neurocognitive impairment measured by RBANS

Time: 6 months after admission at the intensive care unit

Secondary Outcomes

Description: Trail Making Test (TMT) is a test of executive functioning, visual search speed, scanning, speed of processing and mental flexibility. The total score is the time in seconds spent to complete each part.

Measure: Neurocognitive impairment measured by TMT

Time: 6 months after admission at the intensive care unit

Description: The short IQCODE is a 16 question long questionnaire that assesses cognitive impairment in elderly patients. An informant is required to rate a patient's cognitive changes over a 10 year time period. Each question is scored from 1 (much improved over time) to 5 (much worse).

Measure: Neurocognitive impairment by the short IQCODE

Time: 6 months after admission at the intensive care unit
7 MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19

This study evaluates and rehabilitates the cognitive functions of attention, memory, visual perception, language, and executive by the mentalPlus® digital game of COVID-19 surviving patients after remission of symptoms.

NCT04632719
Conditions
  1. Cognitive Impairment
  2. Covid19
  3. Cognitive Dysfunction
  4. Depression, Anxiety
  5. Quality of Life
Interventions
  1. Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Description: The evaluation of cognitive functions by the digital game MentalPlus® (a scale of assessment and cognitive rehabilitation) will take place as follows: Scores range from 0 [Not improved] to 10 [fully improved] at cognitive functions memory, attention and executive after training with Scale. This game is already validated and standardized for the global population. The test takes 25 minutes to play, is playful and self-explanatory. It has twelve themes with cognitive functions: short and long-term memory; selective, alternate and concentrated attention, inhibitory control of executive function and visual perception. MentalPlus® is completely randomized in its phases and themes. Therefore, the game can be used for cognitive assessment with a single theme (25 minutes of execution) or rehabilitation on 10 more themes and a final theme for reassessment of cognitive functions.

Measure: Assessment of cognitive functions after COVID-19

Time: 1 year

Secondary Outcomes

Description: Rehabilitation of cognitive functions: executive, attention, memory, visual perception, language, after the remission of the symptoms of COVID-19. MentalPlus® will be used in order to rehabilitate the cognitive functions of patients who have dysfunctions after COVID-19. The patient will play on alternate days (every other day) a theme of the game and will be rehabilitated through its 10 themes. At the end of these 10 themes, the patient will be reassessed by the last theme of the game, comprising a total of 12 themes. Each theme lasts for 25 minutes each.

Measure: Rehabilitation of cognitive functions after COVID-19

Time: 1 year
8 Improving Thinking in Everyday Life: Pilot Study C

The purpose of this initial study is to evaluate a new form of cognitive rehabilitation therapy for improving your ability to think, particularly how rapidly you process information that you receive from your senses, e.g., sight, hearing, and smell. The study will also test how often and how well you carry out tasks that rely on thinking in your daily life. You will be randomly assigned to receive the new therapy soon or about six months later. In other words, your treatment schedule will be determined by chance. The new therapy involves intensive, repetitive cognitive exercises (up to 3.5hr/day for 10 consecutive weekdays) with rest periods interspersed as needed.

NCT04644172
Conditions
  1. Covid-19
  2. Cognitive Impairment
Interventions
  1. Behavioral: Speed of Processing Training
  2. Behavioral: Instrumental Activities of Daily Living Shaping
  3. Behavioral: Transfer Package from CI Therapy
  4. Other: Usual Care
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Description: The COPM is a widely used, transdiagnostic, individualized, structured interview that detects changes over time in a respondent's performance of five, self-selected activities of daily living (ADL). In this case, the instrument will be completed by a family caregiver and only assess instrumental ADL (IADL) with important cognitive components. Performance is rated using 10-point scale that ranges from 1-10 scale points. High scores reflect effective performance. The test score is the mean of the ratings of the five, self-selected IADL.

Measure: Canadian Occupation Performance Measure (COPM)

Time: Change from Day 0 to Day 17

Secondary Outcomes

Description: The INCA gathers a comprehensive record of participant changes in everyday Instrumental Activities of Daily Living (IADL) with important cognitive components that have been observed since the start of training. These can be reported by the participant (when possible), the caregiver, or other friends and family that have spent time with the participant. The test score is a count; it is the number of new and improved activities with important cognitive components that a participant has been observed to undertake in their daily life since beginning training. The range is 0 to infinite.

Measure: Improved and New Cognitive Ability (INCA)

Time: Change from Day 0 to Day 17

Description: The CTAL quantifies how well and independently participants complete activities of daily living (ADL) and instrumental ADL (IADL) outside the treatment setting. Twenty-two activities with important cognitive components are surveyed; each is rated by the family caregiver using 11-point scales. The How Well Scale is reported here. The range is 0-10 scale points; high scores reflect effective performance of the activities.

Measure: Cognitive Task Activity Log (CTAL) How Well Scale

Time: Change from Day 0 to Day 17

Description: The CTAL quantifies how well and independently participants complete activities of daily living (ADL) and instrumental ADL (IADL) outside the treatment setting. Twenty-two activities with important cognitive components are surveyed; each is rated by the family caregiver using 11 point scales. The Independence Scale is reported. The range is 0-10 scale points; high scores reflect performance of the activities without assistance from others.

Measure: Cognitive Task Activity Log (CTAL) Independence Scale

Time: Change from Day 0 to Day 17

Description: The Assessment of Motor & Process Skills is a widely used, transdiagonistic performance test. Patients will be asked to perform four typical IADL with important cognitive components in the lab. The tasks will be selected from a bank of 125 standardized, Rasch-calibrated tasks. Two sets of four tasks of similar difficulty and type will be assembled and presented in counterbalanced order to reduce the influence of any practice or other order effects. Performance will be videotaped and scored by independent raters masked to group assignment and testing order. The Process Scale score only will be calculated. Scores range from -5 to 5 logits. High scores reflect effective performance of the tasks.

Measure: Assessment of Motor and Process Skills (AMPS)

Time: Change from Day 0 to Day 17
9 Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study.

Post-COVID-19 syndrome is an assembly of symptoms, following an infection with COVID-19. The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome

NCT04647656
Conditions
  1. Covid19
  2. Neurocognitive Dysfunction
Interventions
  1. Device: Hyperbaric oxygen
  2. Device: Sham
MeSH:Cognitive Dysfunction
HPO:Cognitive impairment Mental deterioration

Primary Outcomes

Description: Memory, attention and information process will be evaluated using the NeuroTrax computerized cognitive evaluation battery.

Measure: Cognitive health assessment (NeuroTrax)

Time: Baseline, 2 months

Secondary Outcomes

Description: Cerebral blood volume and flow will be measured using perfusion MRI protocol Dynamic susceptibility contrast (DSC).

Measure: Brain perfusion

Time: Baseline, 2 months

Description: Fractional anisotropy (FA) and Mean diffusivity (MD) will be evaluated using diffusion tensor imaging (DTI) MRI protocol

Measure: Brain microstructure Brain microstructure

Time: Baseline, 2 months

Description: Resting state fMRI (rsfMRI), and task based fmri will evaluate brain function during a working memory task

Measure: Brain function imaging

Time: Baseline, 2 months

Description: Self-reported questionnaire covers the most common symptoms related to post-COVID19 disease

Measure: Post-COVID-19 symptom

Time: Baseline, 2 months

Description: SF-36 questionnaire for self reporting qulity of life

Measure: Quality of Life SF-36

Time: Baseline, 2 months

Description: The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality

Measure: The Pittsburgh Sleep Quality Index PSQI

Time: Baseline, 2 months

Description: The BSI-18 will be used to evaluate psychological distress. The BSI-18 is an 18 item self-report questionnaire which generates a summary scale, the global stress index (GSI), and three subscales: depression, anxiety, and somatization

Measure: The Brief Symptom Inventory - 18 (BSI-18)

Time: Baseline, 2 months

Description: The BPI is a short, self-administered questionnaire. It contains 15 items, which include 2 multi-item scales measuring pain intensity and the impact of pain on functioning and well-being.

Measure: BPI - Brief pain inventory (short form)

Time: Baseline, 2 months

Description: Static balance will be assessed by the Balance Error Scoring System (BESS); Dynamic balance and risk of falling will be assessed by the Timed Up and Go test (TUG) and 10-meter walk (10MW). Muscle function will be assessed by the sit to stand (STS) test for the leg strength and endurance and hand-held dynamometry (HHD) for the isometric grip strength. The sub-maximal aerobic capacity and endurance will be assessed by the 6-minute walk test (6MWT).

Measure: Neuro-physical evaluation

Time: Baseline, 2 months

Description: The neurological exam will include tests of the cranial nerves, motor, sensory and cerebellar function and gait

Measure: Neurological evaluation

Time: Baseline, 2 months

Description: Smell will be tested through smell identification kits to test for odour detection, discrimination and threshold. The kit is standardized for age and gender, and available in different languages (Sniffin' sticks). Taste will be tested on bilateral anterior and posterior parts of the tongue by four tastes: bitter, sour, salt and sweet ("The Taste Strip Test").

Measure: Smell and taste evaluations.

Time: Baseline, 2 months

Description: The cardiopulmonary exercise test (CPET) is a non-invasive measurement of the cardiovascular system, respiratory system and muscles.

Measure: Cardiopulmonary exercise test

Time: Baseline, 2 months

Description: Conventional echocardiography evaluation, linear, volumetric and Doppler measurements will be performed to assess cardiac functions.

Measure: Echocardiography

Time: Baseline, 2 months

Description: Measurements of pulmonary functions will be performed using the MiniSpir testing apparatus.

Measure: Lung functions test

Time: Baseline, 2 months

Description: Blood tests will evaluate immune system including cytokines, CRP and COVID-19 antibodies

Measure: Immune system

Time: Baseline, 2 months

HPO Nodes


HP:0001268: Mental deterioration
Genes 500
SPG11 WDR45 NOTCH2NLC EEF1A2 ALDH18A1 ND6 TIMM8A TUBA4A TRNL1 TRNK VPS35 PNPLA6 TRNC SLC20A2 DRD3 NECAP1 ERCC6 HNRNPA2B1 CNKSR2 HFE GABRG2 APP RRM2B UCP2 TRNS2 NR4A2 GRN APP ATP13A2 MYORG TTR AARS2 DNM1 STXBP1 ITM2B ATXN10 ND1 KCNJ11 ARSA IRF6 ATXN8OS SYNJ1 C9ORF72 CSTB AARS1 ATP6 LRRK2 PSAP COMT PRDX1 GBA NDUFA6 PODXL VPS13C TBK1 PDGFRB SQSTM1 CYP27A1 TREX1 COX1 PMPCA TIMM8A TYROBP PRKAR1B HCN1 GNAS GCH1 ATN1 MTHFR CLTC VCP PSEN1 L1CAM GABRA5 PDGFB PTS ATP6V0A2 C9ORF72 SUMF1 UBQLN2 SLC1A2 PANK2 PSEN1 ATP6 SDHAF1 GABRB2 MAPT TRNW MAPT KMT2A TMEM106B NOTCH2NLC DNAJC5 SNCA MPO SCN1A NTRK2 CLN3 PDGFRB CDK19 TRNW RRM2B CST3 ATP6V1E1 GRN ITM2B MFSD8 CHMP2B SQSTM1 CHD2 GALC ROGDI HNF4A ADA2 ACTL6B MATR3 GALC PRDM8 SNCA RNF216 ERCC8 ATP1A3 KCNB1 CTC1 GBA PSAP FA2H SCARB2 ABCA7 YWHAG PSEN2 ADH1C VPS13A RNF216 APOE TRNS1 TRNH ABCD1 COX1 CSF1R COASY FMR1 TREM2 ATXN2 SCO2 ATXN2 ARSA FTL DCAF17 MATR3 DNM1L FBXO7 ND1 ATXN7 DAOA ND4 NRAS AP2M1 TRNF AUH MBTPS2 APP DALRD3 GRN PANK2 KCNA2 QDPR TRNQ APP TOMM40 PRNP HNF1A HTRA1 RBM28 TRNS1 PSEN1 A2M HTT SLC2A3 ERCC8 PLP1 BSCL2 DNMT1 HNRNPA2B1 MECP2 SLC44A1 NOTCH3 CHMP2B JAM2 TRNK TBK1 CYTB C9ORF72 TREM2 GABRA2 SUMF1 HMBS MMACHC ABCC8 NPC1 CUBN PSEN2 SYNGAP1 SNCB GBA CREBBP AP3B2 ZFYVE26 APP PPT1 TRNF VPS13C NPC2 NUS1 NHLRC1 VCP HTT IDUA TUBB4A FGF12 SQSTM1 EPM2A TRNS2 DNM1 TREM2 PLA2G6 CHCHD10 PSEN1 EPM2A TYROBP PINK1 SNORD118 TYMP VCP SLC13A5 PLAU SNCA C19ORF12 DNAJC6 CLN5 SNCA HLA-DQB1 SCN8A JPH3 C19ORF12 HTR2A PRKN ACTB APP CUX2 IDS SPG21 CHMP2B PPP2R2B CHI3L1 NDP DNAJC13 ARSA GALC SQSTM1 AP5Z1 PLP1 SORL1 FA2H MAPT CSTB SLC13A5 NHLRC1 SNCA DGUOK COL4A1 CHMP2B PSAP RBM28 TARDBP TTPA POLG PRNP CACNA1A MAPT MAPT GBA MAPT TRPM7 NDUFB8 CREBBP KCTD7 APOL4 ATP6V1A TMEM106B CFAP43 VPS13A PDGFRB RRM2B WWOX ATP13A2 SYNJ1 ATXN2 MAPT TARDBP FMR1 SPG11 ATP1A2 DISC2 CTNS SYNJ1 TBK1 TBP DCTN1 SDHB RNASEH1 ROGDI GBA2 SGPL1 GCDH SNCA ADA2 NOTCH3 XPR1 APOL2 CTSD ATP7B DARS2 MAPT EP300 ATP6V1A BSCL2 ARV1 PDE10A SYN2 HTRA2 SPAST SZT2 ND6 SPG21 LRRK2 ATP13A2 PDE11A PPP2R2B TK2 MMACHC DNMT1 GBE1 IDS LMNB1 SMC1A FTL OPA1 CACNA1B TRNQ C9ORF72 HEXB RAB39B CISD2 ERCC2 PLA2G6 MTHFR ALDH18A1 GBA MFN2 HEPACAM VCP COX2 SERPINI1 KCNC1 PARK7 GRN SYNJ1 COX3 EIF4G1 GRIN2D LRRK2 CLN6 CERS1 MCOLN1 NBN PRKCG MAPT TRNE RTN4R MAPT TIMMDC1 NDUFAF3 PRDM8 WFS1 PRNP FA2H PSEN1 SDHD ERCC6 GIGYF2 APTX DLAT UBTF PRNP CNTNAP2 GLUD2 HTT CSF1R PPP3CA TBP DMPK WDR45 PSAP PRICKLE1 PDGFB PRNP SURF1 GABRB3 APP HEXA PSEN1 TREX1 VCP GBA TWNK HGSNAT CYFIP2 KCNA2 TRNV TRAK1 MAPK10 UBA5 ATP13A2 DNMT1 COX2 FUS CHD2 NDUFS2 PARS2 HIBCH HTRA1 MAPT SCN1A CTSF ND5 CHMP2B DHDDS ATXN3 CLN6 VCP PLEKHG4 NAGLU GBA2 POLG TRNL1 TLR3 PRNP GRN GDAP2 HNRNPA1 LYST GBA SNCAIP ATN1 CLN8 TMEM106B GALC CP XPA ND5 ATXN7 HSD17B10 COL18A1 TBP COX6B1 MAPT PRNP TINF2 PSEN1 APOE TREM2 PINK1 UBAP1 TREM2 GM2A SCN3A GLB1 C9ORF72 WFS1 ASAH1 DCTN1 PRKAR1A PLA2G6 TREM2 MAPT NOS3 COX3 JPH3 RAB27A SLC6A1 ERCC4 PRNP PAH UCHL1 ABCD1 CHCHD10 ASAH1 CLN8 SDHA
Protein Mutations 3
K56M V158M V66M
HP:0100543: Cognitive impairment
Genes 890
ACSF3 SPG11 NOTCH2NLC EEF1A2 ALDH18A1 TIMM8A GRID2 TRNK GDF5 TRNC DRD3 HNRNPA2B1 CNKSR2 HFE PRKRA GNAS APP STARD7 UCP2 NR4A2 APP EDN3 SLC5A7 MYORG SPG11 STXBP1 ITM2B ATXN10 ND1 ATP1A3 ARSA ATXN3 POLG ATXN8OS PEX11B PLP1 FKTN AARS1 ATP6 SLC30A9 DCX LRRK2 COMT GBA NDUFA6 ATG5 SCN1A VPS13C ROBO3 NF1 TBK1 POMK TREX1 ABCA7 PMPCA TYROBP PRKAR1B PIK3CA HCN1 TWNK GCH1 COL3A1 ATN1 TSC2 MTHFR TSC1 VCP L1CAM CFHR1 GABRA5 ITPR1 ADD3 LIPN ATP6V0A2 RNR1 UBQLN2 SLC1A2 PANK2 ATP6 SOST METTL23 MAPT TRNW MAPT KMT2A TMEM106B TTC19 ERCC3 SNCA MPO ERCC3 SCN1A CLN3 RRM2B MTO1 SCN1B CST3 ATP6V1E1 GRN PEX19 MFSD8 SMC3 SQSTM1 COQ2 ARL6IP6 CHD2 ZNF365 GALC HNF4A ADA2 ACTL6B PRDM8 SNCA RNF216 ERCC8 CENPJ KCNB1 NAGS PSAP SLC18A2 FA2H ABCA7 FAN1 PSEN2 ATXN1 COX1 MTOR CSF1R STXBP1 SDHA REEP2 FMR1 TREM2 ATXN2 SCO2 ARSA ERCC2 DCAF17 ATXN3 FBN1 GDNF ATXN7 ND4 KCND3 NRAS AP2M1 AUH MBTPS2 POLG IFT140 GRN RBM12 BAP1 KCNA2 MAG APP PRNP HNF1A COASY LAMA1 SMARCB1 A2M HTT MARS2 SLC25A15 CEP120 MSH6 CYP4F22 ERCC8 BSCL2 MEFV GJC2 HNRNPA2B1 GABRG2 SLC44A1 NOTCH3 JAM2 TRNK LAMA2 CYTB GABRA2 HMBS ABCC8 EIF2B3 NPC1 SYNGAP1 CREBBP PEX6 ATXN1 ZFYVE26 NPC2 ALMS1 CP VCP HTT IDUA LAMP2 TUBB4A FGF12 SQSTM1 EPM2A TRNS2 FKRP TREM2 PLA2G6 PSEN1 EPM2A IL12A-AS1 KLLN PINK1 SNORD118 TYMP SLC13A5 C12ORF65 UQCRC2 SPG7 HLA-DRB1 DGUOK STUB1 CENPE TSC2 BRAF JPH3 AASS C19ORF12 IL12A CEP152 PRKN WDR73 POLG2 KMT2B APP XPC CUX2 CHI3L1 NDP GALC ECM1 EIF2B5 PLP1 SORL1 TSFM FLNA DGUOK RBM28 SIGMAR1 TARDBP TTPA CACNA1A MAPT PEX10 GBA GBE1 SULT2B1 SDR9C7 KCTD7 TMEM106B GMPPB C12ORF65 XPA GNAS SIM1 RRM2B WWOX KATNB1 ATP13A2 SYNJ1 FMR1 DISC2 SPTBN2 PNKP TBP DCTN1 TP53 PLAA FGF14 HSD17B4 GCDH SNCA ADA2 SDHAF1 GTPBP3 APOL2 ALG2 CTSD TWNK CCM2 ATP7B DARS2 ALG9 DSG4 EP300 SPART STUB1 EIF2B4 PMS1 BBS5 TTC37 STAT4 KRT86 SPG21 PDE11A FAS TK2 NPHP1 DNMT1 LMNB1 WDR4 PCNT C9ORF72 KRT83 RAB39B CISD2 POLG DCC ERCC2 SCN1A PLA2G6 GJB6 SCN8A TK2 MLH1 HEPACAM CENPJ VCP SERPINI1 PARK7 COX3 GRIN2D LRRK2 USF3 CLN6 GNPTAB CTSK CERS1 MCOLN1 POLG ERF NBN PRKCG GRID2 DOLK GABRA1 MAPT NDUFAF3 CFH SPTBN2 WFS1 FA2H PSEN1 ERCC6 IBA57 UBTF MYO1H VPS37A CNTNAP2 PIK3CA UBA1 SEMA4A HTT SCN2A DMPK PSAP ERCC5 PRICKLE1 TRNS2 PRNP SURF1 LARS2 APP PSEN1 TREX1 VCP DNAJC6 GBA CHRNG IRAK1 POMT1 TRAK1 PEX12 BDNF ATP13A2 DNMT1 FUS CHD2 NDUFS2 HIBCH HTRA1 MAPT SCN1A CTSF ND5 ATXN3 DZIP1L VCP NUP107 PNKP GBA2 POLG TLR3 PRNP C9ORF72 SCN1B HNRNPA1 CTNS CYP2U1 SNCAIP ATN1 LAGE3 TBCK MLH3 TMEM106B GALC CP COL18A1 ALG13 GPC4 COX6B1 MAPT GDF6 GABRD TINF2 PSEN1 APOE TREM2 MYH3 ADGRV1 PINK1 TREM2 SPG7 MOG SCN3A SDHD GLB1 C9ORF72 WFS1 ASAH1 DCTN1 PRKAR1A AFG3L2 ATR PLA2G6 MAPT NOS3 KRT81 JPH3 ITPR1 RAB27A SLC6A1 ERCC4 UCHL1 TRNS1 ABCD1 ALOXE3 TRNH WDR45 ND6 TUBA4A TRNL1 GNE MEN1 VPS35 PNPLA6 SLC20A2 NECAP1 ERCC6 DDB2 GABRG2 RRM2B TRNS2 GRN ATP13A2 TTR AARS2 GJB2 DNM1 KCNJ11 IRF6 SYNJ1 C9ORF72 PTEN CSTB NFIA POMT2 OCRL PSAP PEX13 PRDX1 ABCA12 TGFBR2 PODXL SPAST CRLF1 CAMTA1 PDGFRB SQSTM1 CYP27A1 B3GALNT2 BAP1 COX1 TGM1 FOXG1 TIMM8A MYD88 GNAS CLTC PORCN PSEN1 PMS2 SEC23B POLG PDGFB PTS SCN9A CYP7B1 PKHD1 C9ORF72 SUMF1 RBBP8 PSEN1 SDHAF1 GABRB2 TRNL1 NOTCH2NLC SPG11 SLC2A1 MEOX1 DNAJC5 PEX2 CCDC78 PRKCG KRAS NTRK2 GLA AP5Z1 PDGFRB CDK19 TRNW OPA3 ITM2B CHMP2B SLC2A1 CYP2U1 ROGDI MATR3 GALC PDCD10 PEX26 BBS10 SLC25A4 ATP1A3 FGD1 CTC1 GBA GSN SCARB2 YWHAG IKBKG ADH1C VPS13A RNF216 APOE TRNS1 TRNH ABCD1 ATP13A2 HCN1 DARS2 COASY SCN2A TSC1 ATXN2 FTL ALOX12B MATR3 BBIP1 SLC7A7 DNM1L GNAS FBXO7 UGT1A1 ND1 DAOA ALS2 SUFU PEX3 TRNF APP DALRD3 PANK2 C4A QDPR TRNQ TOMM40 MPDU1 HTRA1 RBM28 TRNS1 PSEN1 SLC2A3 PEX1 PLP1 CHRM3 FGFR3 DNMT1 P2RY11 EPRS1 TRNQ PLK4 XRCC4 MAOA MECP2 CHMP2B CLCF1 TBK1 C9ORF72 TREM2 SUMF1 GM2A MSH2 GDF3 MMACHC GMPPB KCNT1 CUBN HLA-DQB1 PSEN2 SDHB SNCB GBA SPP1 AP3B2 APP PPT1 AKT1 TRNF VPS13C NUS1 NHLRC1 PEX16 TRAF7 GJC2 DNM1 TNFSF4 RNASEH1 CHCHD10 TYROBP RMRP TMEM240 VCP PLAU SNCA C19ORF12 DNAJC6 CLN5 SNCA HLA-DQB1 ERCC4 SCN8A PEX14 HTR2A TRNP ACTB PEX16 ND5 IDS PANK2 SPG21 CHMP2B C12ORF65 CLMP PPP2R2B NAGS DNAJC13 ARSA RPS20 SQSTM1 AP5Z1 CACNA1G FA2H SMO MAPT CSTB SCN9A SLC13A5 NHLRC1 AFG3L2 SNCA COL4A1 CHMP2B PSAP FGF14 ATM POLG PRNP MAPT NKX6-2 MAPT TRPM7 NDUFB8 SMC1A CREBBP VAMP1 PDGFB APOL4 ATP6V1A MTFMT ABCA5 CFAP43 EPCAM VPS13A IL10 PDGFRB PANK2 SDCCAG8 ATXN2 MAPT TARDBP SPG11 SDHD ATP1A2 CTNS TRNF PRNP SYNJ1 TUBB2B TBK1 ATRIP ATXN3 SDHB RNASEH1 VAMP1 ROGDI GBA2 SGPL1 RRM2B KRIT1 TRAIP NOTCH3 BBS12 XPR1 SMARCE1 MAPT ATP6V1A BSCL2 ARV1 PDE10A POMGNT1 SYN2 SRCAP HTRA2 SPAST SZT2 ND6 LRRK2 ATP13A2 PPP2R2B SLC18A2 MMACHC GBE1 TMEM240 IDS SMC1A FTL RIN2 OPA1 CACNA1B TRNQ HEXB ITGA7 DNAJC3 EIF2B2 MTHFR ALDH18A1 GBA MFN2 COA3 IL23R COX2 KCNC1 GRN SYNJ1 EIF4G1 NUP133 MAPT LTBP4 TRNE RTN4R PIK3CA LARGE1 TIMMDC1 PRDM8 PRNP SDHD SLC25A4 SLC25A13 SDHC GIGYF2 TLR4 APTX DLAT TERT PRNP DSTYK KIF5A GLUD2 PCDH19 CSF1R PPP3CA TBP AIFM1 WDR45 NF2 NF2 PDGFB GABRB3 HEXA TRNK STAT4 TPRKB TWNK HGSNAT CYFIP2 KCNA2 ALG12 TRNV TWNK OSGEP MAPK10 UBA5 CCR1 COX2 EIF2B1 UBAC2 PTPN22 TTC8 PARS2 BMPR1A FAS CFHR3 CHMP2B DHDDS CLN6 ERAP1 PLEKHG4 NAGLU TRNL1 GRN GDAP2 PEX5 PHOX2B AKT1 LYST GBA STX1B DMD CLN8 TP53RK XPA ND5 ATXN7 HSD17B10 TBP KLRC4 B3GALNT2 MAGEL2 PRNP LZTFL1 UBAP1 HCRT GM2A CTDP1 FUS TREM2 SEC61A1 NAGA GABRG2 COX3 NIPAL4 ADAMTSL4 PRNP SPR PAH CTSH POMT2 CHCHD10 ASAH1 CLN8 HLA-B SDHA
Protein Mutations 0
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0001268: Mental deterioration
Genes 500
SPG11 WDR45 NOTCH2NLC EEF1A2 ALDH18A1 ND6 TIMM8A TUBA4A TRNL1 TRNK VPS35 PNPLA6 TRNC SLC20A2 DRD3 NECAP1 ERCC6 HNRNPA2B1 CNKSR2 HFE GABRG2 APP RRM2B UCP2 TRNS2 NR4A2 GRN APP ATP13A2 MYORG TTR AARS2 DNM1 STXBP1 ITM2B ATXN10 ND1 KCNJ11 ARSA IRF6 ATXN8OS SYNJ1 C9ORF72 CSTB AARS1 ATP6 LRRK2 PSAP COMT PRDX1 GBA NDUFA6 PODXL VPS13C TBK1 PDGFRB SQSTM1 CYP27A1 TREX1 COX1 PMPCA TIMM8A TYROBP PRKAR1B HCN1 GNAS GCH1 ATN1 MTHFR CLTC VCP PSEN1 L1CAM GABRA5 PDGFB PTS ATP6V0A2 C9ORF72 SUMF1 UBQLN2 SLC1A2 PANK2 PSEN1 ATP6 SDHAF1 GABRB2 MAPT TRNW MAPT KMT2A TMEM106B NOTCH2NLC DNAJC5 SNCA MPO SCN1A NTRK2 CLN3 PDGFRB CDK19 TRNW RRM2B CST3 ATP6V1E1 GRN ITM2B MFSD8 CHMP2B SQSTM1 CHD2 GALC ROGDI HNF4A ADA2 ACTL6B MATR3 GALC PRDM8 SNCA RNF216 ERCC8 ATP1A3 KCNB1 CTC1 GBA PSAP FA2H SCARB2 ABCA7 YWHAG PSEN2 ADH1C VPS13A RNF216 APOE TRNS1 TRNH ABCD1 COX1 CSF1R COASY FMR1 TREM2 ATXN2 SCO2 ATXN2 ARSA FTL DCAF17 MATR3 DNM1L FBXO7 ND1 ATXN7 DAOA ND4 NRAS AP2M1 TRNF AUH MBTPS2 APP DALRD3 GRN PANK2 KCNA2 QDPR TRNQ APP TOMM40 PRNP HNF1A HTRA1 RBM28 TRNS1 PSEN1 A2M HTT SLC2A3 ERCC8 PLP1 BSCL2 DNMT1 HNRNPA2B1 MECP2 SLC44A1 NOTCH3 CHMP2B JAM2 TRNK TBK1 CYTB C9ORF72 TREM2 GABRA2 SUMF1 HMBS MMACHC ABCC8 NPC1 CUBN PSEN2 SYNGAP1 SNCB GBA CREBBP AP3B2 ZFYVE26 APP PPT1 TRNF VPS13C NPC2 NUS1 NHLRC1 VCP HTT IDUA TUBB4A FGF12 SQSTM1 EPM2A TRNS2 DNM1 TREM2 PLA2G6 CHCHD10 PSEN1 EPM2A TYROBP PINK1 SNORD118 TYMP VCP SLC13A5 PLAU SNCA C19ORF12 DNAJC6 CLN5 SNCA HLA-DQB1 SCN8A JPH3 C19ORF12 HTR2A PRKN ACTB APP CUX2 IDS SPG21 CHMP2B PPP2R2B CHI3L1 NDP DNAJC13 ARSA GALC SQSTM1 AP5Z1 PLP1 SORL1 FA2H MAPT CSTB SLC13A5 NHLRC1 SNCA DGUOK COL4A1 CHMP2B PSAP RBM28 TARDBP TTPA POLG PRNP CACNA1A MAPT MAPT GBA MAPT TRPM7 NDUFB8 CREBBP KCTD7 APOL4 ATP6V1A TMEM106B CFAP43 VPS13A PDGFRB RRM2B WWOX ATP13A2 SYNJ1 ATXN2 MAPT TARDBP FMR1 SPG11 ATP1A2 DISC2 CTNS SYNJ1 TBK1 TBP DCTN1 SDHB RNASEH1 ROGDI GBA2 SGPL1 GCDH SNCA ADA2 NOTCH3 XPR1 APOL2 CTSD ATP7B DARS2 MAPT EP300 ATP6V1A BSCL2 ARV1 PDE10A SYN2 HTRA2 SPAST SZT2 ND6 SPG21 LRRK2 ATP13A2 PDE11A PPP2R2B TK2 MMACHC DNMT1 GBE1 IDS LMNB1 SMC1A FTL OPA1 CACNA1B TRNQ C9ORF72 HEXB RAB39B CISD2 ERCC2 PLA2G6 MTHFR ALDH18A1 GBA MFN2 HEPACAM VCP COX2 SERPINI1 KCNC1 PARK7 GRN SYNJ1 COX3 EIF4G1 GRIN2D LRRK2 CLN6 CERS1 MCOLN1 NBN PRKCG MAPT TRNE RTN4R MAPT TIMMDC1 NDUFAF3 PRDM8 WFS1 PRNP FA2H PSEN1 SDHD ERCC6 GIGYF2 APTX DLAT UBTF PRNP CNTNAP2 GLUD2 HTT CSF1R PPP3CA TBP DMPK WDR45 PSAP PRICKLE1 PDGFB PRNP SURF1 GABRB3 APP HEXA PSEN1 TREX1 VCP GBA TWNK HGSNAT CYFIP2 KCNA2 TRNV TRAK1 MAPK10 UBA5 ATP13A2 DNMT1 COX2 FUS CHD2 NDUFS2 PARS2 HIBCH HTRA1 MAPT SCN1A CTSF ND5 CHMP2B DHDDS ATXN3 CLN6 VCP PLEKHG4 NAGLU GBA2 POLG TRNL1 TLR3 PRNP GRN GDAP2 HNRNPA1 LYST GBA SNCAIP ATN1 CLN8 TMEM106B GALC CP XPA ND5 ATXN7 HSD17B10 COL18A1 TBP COX6B1 MAPT PRNP TINF2 PSEN1 APOE TREM2 PINK1 UBAP1 TREM2 GM2A SCN3A GLB1 C9ORF72 WFS1 ASAH1 DCTN1 PRKAR1A PLA2G6 TREM2 MAPT NOS3 COX3 JPH3 RAB27A SLC6A1 ERCC4 PRNP PAH UCHL1 ABCD1 CHCHD10 ASAH1 CLN8 SDHA
Protein Mutations 3
K56M V158M V66M
HP:0100543: Cognitive impairment
Genes 890
ACSF3 SPG11 NOTCH2NLC EEF1A2 ALDH18A1 TIMM8A GRID2 TRNK GDF5 TRNC DRD3 HNRNPA2B1 CNKSR2 HFE PRKRA GNAS APP STARD7 UCP2 NR4A2 APP EDN3 SLC5A7 MYORG SPG11 STXBP1 ITM2B ATXN10 ND1 ATP1A3 ARSA ATXN3 POLG ATXN8OS PEX11B PLP1 FKTN AARS1 ATP6 SLC30A9 DCX LRRK2 COMT GBA NDUFA6 ATG5 SCN1A VPS13C ROBO3 NF1 TBK1 POMK TREX1 ABCA7 PMPCA TYROBP PRKAR1B PIK3CA HCN1 TWNK GCH1 COL3A1 ATN1 TSC2 MTHFR TSC1 VCP L1CAM CFHR1 GABRA5 ITPR1 ADD3 LIPN ATP6V0A2 RNR1 UBQLN2 SLC1A2 PANK2 ATP6 SOST METTL23 MAPT TRNW MAPT KMT2A TMEM106B TTC19 ERCC3 SNCA MPO ERCC3 SCN1A CLN3 RRM2B MTO1 SCN1B CST3 ATP6V1E1 GRN PEX19 MFSD8 SMC3 SQSTM1 COQ2 ARL6IP6 CHD2 ZNF365 GALC HNF4A ADA2 ACTL6B PRDM8 SNCA RNF216 ERCC8 CENPJ KCNB1 NAGS PSAP SLC18A2 FA2H ABCA7 FAN1 PSEN2 ATXN1 COX1 MTOR CSF1R STXBP1 SDHA REEP2 FMR1 TREM2 ATXN2 SCO2 ARSA ERCC2 DCAF17 ATXN3 FBN1 GDNF ATXN7 ND4 KCND3 NRAS AP2M1 AUH MBTPS2 POLG IFT140 GRN RBM12 BAP1 KCNA2 MAG APP PRNP HNF1A COASY LAMA1 SMARCB1 A2M HTT MARS2 SLC25A15 CEP120 MSH6 CYP4F22 ERCC8 BSCL2 MEFV GJC2 HNRNPA2B1 GABRG2 SLC44A1 NOTCH3 JAM2 TRNK LAMA2 CYTB GABRA2 HMBS ABCC8 EIF2B3 NPC1 SYNGAP1 CREBBP PEX6 ATXN1 ZFYVE26 NPC2 ALMS1 CP VCP HTT IDUA LAMP2 TUBB4A FGF12 SQSTM1 EPM2A TRNS2 FKRP TREM2 PLA2G6 PSEN1 EPM2A IL12A-AS1 KLLN PINK1 SNORD118 TYMP SLC13A5 C12ORF65 UQCRC2 SPG7 HLA-DRB1 DGUOK STUB1 CENPE TSC2 BRAF JPH3 AASS C19ORF12 IL12A CEP152 PRKN WDR73 POLG2 KMT2B APP XPC CUX2 CHI3L1 NDP GALC ECM1 EIF2B5 PLP1 SORL1 TSFM FLNA DGUOK RBM28 SIGMAR1 TARDBP TTPA CACNA1A MAPT PEX10 GBA GBE1 SULT2B1 SDR9C7 KCTD7 TMEM106B GMPPB C12ORF65 XPA GNAS SIM1 RRM2B WWOX KATNB1 ATP13A2 SYNJ1 FMR1 DISC2 SPTBN2 PNKP TBP DCTN1 TP53 PLAA FGF14 HSD17B4 GCDH SNCA ADA2 SDHAF1 GTPBP3 APOL2 ALG2 CTSD TWNK CCM2 ATP7B DARS2 ALG9 DSG4 EP300 SPART STUB1 EIF2B4 PMS1 BBS5 TTC37 STAT4 KRT86 SPG21 PDE11A FAS TK2 NPHP1 DNMT1 LMNB1 WDR4 PCNT C9ORF72 KRT83 RAB39B CISD2 POLG DCC ERCC2 SCN1A PLA2G6 GJB6 SCN8A TK2 MLH1 HEPACAM CENPJ VCP SERPINI1 PARK7 COX3 GRIN2D LRRK2 USF3 CLN6 GNPTAB CTSK CERS1 MCOLN1 POLG ERF NBN PRKCG GRID2 DOLK GABRA1 MAPT NDUFAF3 CFH SPTBN2 WFS1 FA2H PSEN1 ERCC6 IBA57 UBTF MYO1H VPS37A CNTNAP2 PIK3CA UBA1 SEMA4A HTT SCN2A DMPK PSAP ERCC5 PRICKLE1 TRNS2 PRNP SURF1 LARS2 APP PSEN1 TREX1 VCP DNAJC6 GBA CHRNG IRAK1 POMT1 TRAK1 PEX12 BDNF ATP13A2 DNMT1 FUS CHD2 NDUFS2 HIBCH HTRA1 MAPT SCN1A CTSF ND5 ATXN3 DZIP1L VCP NUP107 PNKP GBA2 POLG TLR3 PRNP C9ORF72 SCN1B HNRNPA1 CTNS CYP2U1 SNCAIP ATN1 LAGE3 TBCK MLH3 TMEM106B GALC CP COL18A1 ALG13 GPC4 COX6B1 MAPT GDF6 GABRD TINF2 PSEN1 APOE TREM2 MYH3 ADGRV1 PINK1 TREM2 SPG7 MOG SCN3A SDHD GLB1 C9ORF72 WFS1 ASAH1 DCTN1 PRKAR1A AFG3L2 ATR PLA2G6 MAPT NOS3 KRT81 JPH3 ITPR1 RAB27A SLC6A1 ERCC4 UCHL1 TRNS1 ABCD1 ALOXE3 TRNH WDR45 ND6 TUBA4A TRNL1 GNE MEN1 VPS35 PNPLA6 SLC20A2 NECAP1 ERCC6 DDB2 GABRG2 RRM2B TRNS2 GRN ATP13A2 TTR AARS2 GJB2 DNM1 KCNJ11 IRF6 SYNJ1 C9ORF72 PTEN CSTB NFIA POMT2 OCRL PSAP PEX13 PRDX1 ABCA12 TGFBR2 PODXL SPAST CRLF1 CAMTA1 PDGFRB SQSTM1 CYP27A1 B3GALNT2 BAP1 COX1 TGM1 FOXG1 TIMM8A MYD88 GNAS CLTC PORCN PSEN1 PMS2 SEC23B POLG PDGFB PTS SCN9A CYP7B1 PKHD1 C9ORF72 SUMF1 RBBP8 PSEN1 SDHAF1 GABRB2 TRNL1 NOTCH2NLC SPG11 SLC2A1 MEOX1 DNAJC5 PEX2 CCDC78 PRKCG KRAS NTRK2 GLA AP5Z1 PDGFRB CDK19 TRNW OPA3 ITM2B CHMP2B SLC2A1 CYP2U1 ROGDI MATR3 GALC PDCD10 PEX26 BBS10 SLC25A4 ATP1A3 FGD1 CTC1 GBA GSN SCARB2 YWHAG IKBKG ADH1C VPS13A RNF216 APOE TRNS1 TRNH ABCD1 ATP13A2 HCN1 DARS2 COASY SCN2A TSC1 ATXN2 FTL ALOX12B MATR3 BBIP1 SLC7A7 DNM1L GNAS FBXO7 UGT1A1 ND1 DAOA ALS2 SUFU PEX3 TRNF APP DALRD3 PANK2 C4A QDPR TRNQ TOMM40 MPDU1 HTRA1 RBM28 TRNS1 PSEN1 SLC2A3 PEX1 PLP1 CHRM3 FGFR3 DNMT1 P2RY11 EPRS1 TRNQ PLK4 XRCC4 MAOA MECP2 CHMP2B CLCF1 TBK1 C9ORF72 TREM2 SUMF1 GM2A MSH2 GDF3 MMACHC GMPPB KCNT1 CUBN HLA-DQB1 PSEN2 SDHB SNCB GBA SPP1 AP3B2 APP PPT1 AKT1 TRNF VPS13C NUS1 NHLRC1 PEX16 TRAF7 GJC2 DNM1 TNFSF4 RNASEH1 CHCHD10 TYROBP RMRP TMEM240 VCP PLAU SNCA C19ORF12 DNAJC6 CLN5 SNCA HLA-DQB1 ERCC4 SCN8A PEX14 HTR2A TRNP ACTB PEX16 ND5 IDS PANK2 SPG21 CHMP2B C12ORF65 CLMP PPP2R2B NAGS DNAJC13 ARSA RPS20 SQSTM1 AP5Z1 CACNA1G FA2H SMO MAPT CSTB SCN9A SLC13A5 NHLRC1 AFG3L2 SNCA COL4A1 CHMP2B PSAP FGF14 ATM POLG PRNP MAPT NKX6-2 MAPT TRPM7 NDUFB8 SMC1A CREBBP VAMP1 PDGFB APOL4 ATP6V1A MTFMT ABCA5 CFAP43 EPCAM VPS13A IL10 PDGFRB PANK2 SDCCAG8 ATXN2 MAPT TARDBP SPG11 SDHD ATP1A2 CTNS TRNF PRNP SYNJ1 TUBB2B TBK1 ATRIP ATXN3 SDHB RNASEH1 VAMP1 ROGDI GBA2 SGPL1 RRM2B KRIT1 TRAIP NOTCH3 BBS12 XPR1 SMARCE1 MAPT ATP6V1A BSCL2 ARV1 PDE10A POMGNT1 SYN2 SRCAP HTRA2 SPAST SZT2 ND6 LRRK2 ATP13A2 PPP2R2B SLC18A2 MMACHC GBE1 TMEM240 IDS SMC1A FTL RIN2 OPA1 CACNA1B TRNQ HEXB ITGA7 DNAJC3 EIF2B2 MTHFR ALDH18A1 GBA MFN2 COA3 IL23R COX2 KCNC1 GRN SYNJ1 EIF4G1 NUP133 MAPT LTBP4 TRNE RTN4R PIK3CA LARGE1 TIMMDC1 PRDM8 PRNP SDHD SLC25A4 SLC25A13 SDHC GIGYF2 TLR4 APTX DLAT TERT PRNP DSTYK KIF5A GLUD2 PCDH19 CSF1R PPP3CA TBP AIFM1 WDR45 NF2 NF2 PDGFB GABRB3 HEXA TRNK STAT4 TPRKB TWNK HGSNAT CYFIP2 KCNA2 ALG12 TRNV TWNK OSGEP MAPK10 UBA5 CCR1 COX2 EIF2B1 UBAC2 PTPN22 TTC8 PARS2 BMPR1A FAS CFHR3 CHMP2B DHDDS CLN6 ERAP1 PLEKHG4 NAGLU TRNL1 GRN GDAP2 PEX5 PHOX2B AKT1 LYST GBA STX1B DMD CLN8 TP53RK XPA ND5 ATXN7 HSD17B10 TBP KLRC4 B3GALNT2 MAGEL2 PRNP LZTFL1 UBAP1 HCRT GM2A CTDP1 FUS TREM2 SEC61A1 NAGA GABRG2 COX3 NIPAL4 ADAMTSL4 PRNP SPR PAH CTSH POMT2 CHCHD10 ASAH1 CLN8 HLA-B SDHA
Protein Mutations 0
SNP 0

Reports

Data processed on January 01, 2021.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook